Review on lipegfilgrastim
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we...
Enregistré dans:
Auteurs principaux: | Gasparic M, Leyman S |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/71f97796db5a4d8f91a8d2a32e5ba85e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
par: Hoggatt J, et autres
Publié: (2015) -
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
par: Hoggatt J, et autres
Publié: (2015) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
par: Guariglia R, et autres
Publié: (2016) -
Thermosensitive liposomal drug delivery systems: state of the art review
par: Kneidl B, et autres
Publié: (2014) -
Application of supercritical antisolvent method in drug encapsulation: a review
par: Kalani M, et autres
Publié: (2011)